Clinical Trial Update: 89Zr-RO5323441 PET Imaging in Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the PET imaging agent 89Zr-RO5323441 for glioblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• 89Zr-RO5323441 (RO5323441 radiolabeled PET imaging agent)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Glioblastoma | Phase 2 | Status: WITHDRAWN